VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...
Yahoo Finance4d
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company expects the ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid ...
Investing4d
Vertex Pharmaceuticals' stock edges higher on top-line beat, strong guidance
BOSTON - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported fourth-quarter revenue that exceeded analyst estimates, driving its stock up 0.8% in after-hours trading Monday. The biotechnology ...
Investing10d
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
STAT14d
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...
UK health system to offer cutting-edge gene therapy for sickle cell disease
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.
SpotDraft Secures $54 Million To Lead AI Contract Lifecycle Management
SpotDraft, the CLM platform that helps in-house legal teams manage their contract ecosystems, has raised $54 million in ...
health.economictimes.indiatimes14d
UK health system to offer cutting-edge gene therapy for sickle cell disease
The therapy from Vertex Pharmaceuticals and CRISPR Therapeutics will cost the state-funded healthcare system around 1.65 million pounds ($2.1 million) per course. Britain's MHRA medical regulator ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food ...
FDA approves new type of non-opioid pain medication in two decades
The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin, the first of its kind in 20 years.